Centene reported $1.1 billion in net profit for the second quarter of 2026, reversing a $253 million loss in the same period a year earlier. The company also raised its full-year guidance and increased its revenue outlook after posting stronger-than-expected results for the quarter.
At the midpoint of 2026, Centene’s cumulative profit was $2.6 billion, compared with $1.05 billion through the first two quarters of 2025, according to the company’s earnings report released Tuesday morning. The quarter’s results surpassed Wall Street expectations for both profit and revenue, per Zacks Investment Research.
Centene recorded $53.6 billion in revenue in Q2 2026, up from $48.7 billion in Q2 2025. On a half-year basis, revenue reached $103.5 billion, versus $95.4 billion through the first half of 2025.
Following the quarter, the company raised its full-year 2026 earnings guidance to at least $4.80 per share. It also revised up its revenue outlook to a range of $193.5 billion to $197.5 billion for the year.
CEO Sarah London said the performance “represent[s] meaningful milestones on our path to restoring profitability and increasing shareholder value.” She added that the company remains focused on delivering strong health outcomes while controlling costs.
One of the drivers Centene cited for its improved results was better management of medical costs. The company’s overall medical loss ratio (MLR) for the quarter was 89.6%, down from 93% in the prior-year quarter. Centene attributed that improvement to stronger pricing in its marketplace plans and “tangible progress in managing medical costs in the Medicaid business,” as noted in the earnings release.
Commercial plan performance also improved: the MLR for Centene’s commercial plans was 79.2% in the quarter, a figure highlighted in the report as a positive development.
Total membership at the end of Q2 stood at 25.9 million, down from 28 million in Q2 2025. The largest element of that decline was in the company’s Affordable Care Act (ACA) marketplace plans, where enrollment fell from 5.9 million to 3.5 million. Centene said that decrease was in line with its expectations.
The company has previously taken actions related to ACA market dynamics; this quarter’s enrollment changes reflect those ongoing shifts in its marketplace footprint.
Analysts tracked by Zacks Investment Research said Centene beat expectations on both revenue and profit for the quarter. Management framed the results as evidence of momentum in restoring profitability and improving cost structure.
Statements in the press release emphasized the combination of pricing improvements in marketplace products and operational progress in Medicaid as the principal contributors to the quarter’s improved margins and earnings.
On the basis of Q2 performance, Centene increased its fiscal-year guidance for both earnings per share and revenue. The company cited its focus on delivering industry-leading health outcomes alongside a leaner cost structure as the strategy it will continue to pursue.
The earnings release did not provide additional specific operational actions or a detailed breakdown of expected quarterly trends for the remainder of 2026 beyond the revised full-year guidance and the reasons for improvements already cited (marketplace pricing and Medicaid cost management).
Centene’s rebound to profitability and its upward revision of guidance arrive amid ongoing adjustments across the health insurance sector to pricing, membership shifts in ACA marketplaces and efforts to contain medical costs in Medicaid programs. For Centene, the quarter combined higher revenue with an improved medical loss ratio to produce materially stronger earnings compared with the prior year.
Investors and observers will likely watch upcoming quarterly updates for evidence that the company can sustain the lower MLRs and the membership trends that supported the revised guidance. The company’s own statements indicate those are key areas of focus, but the earnings report did not include detailed forward-looking operational milestones beyond the adjusted financial targets.
Centene’s Q2 2026 results showed a significant swing to profitability, higher revenue, and improved cost metrics. The company responded by raising its full-year EPS target to at least $4.80 and increasing its 2026 revenue range to $193.5 billion–$197.5 billion, while noting continuing work on pricing and Medicaid cost management to sustain the gains reported in the quarter.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.